Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.

MLA

Levy, Dan, et al. “Significance of Sjögren’s Syndrome and Anti-CN1A Antibody in Myositis Patients.” Rheumatology (Oxford, England), vol. 61, no. 2, Feb. 2022, pp. 756–63. EBSCOhost, https://doi.org/10.1093/rheumatology/keab423.

APA

Levy, D., Nespola, B., Giannini, M., Felten, R., Severac, F., Varoquier, C., Rinagel, M., Korganow, A.-S., Martin, T., Poindron, V., Maurier, F., Chereih, H., Bouldoires, B., Hervier, B., Lenormand, C., Chatelus, E., Geny, B., Sibilia, J., Arnaud, L., … Meyer, A. (2022). Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology (Oxford, England), 61(2), 756–763. https://doi.org/10.1093/rheumatology/keab423

Chicago

Levy, Dan, Benoit Nespola, Margherita Giannini, Renaud Felten, François Severac, Coralie Varoquier, Marina Rinagel, et al. 2022. “Significance of Sjögren’s Syndrome and Anti-CN1A Antibody in Myositis Patients.” Rheumatology (Oxford, England) 61 (2): 756–63. doi:10.1093/rheumatology/keab423.